Modality
Peptide
MOA
Cl18.2
Target
APOC3
Pathway
PI3K/AKT
SLEPsA
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
~Dec 2017
→ ~Mar 2019
Phase 2
~Jun 2019
→ ~Sep 2020
Phase 3
~Dec 2020
→ ~Mar 2022
NDA/BLA
Jun 2022
→ Sep 2027
NDA/BLACurrent
NCT08052990
649 pts·SLE
2022-06→2027-09·Recruiting
649 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-09-191.5y awayPh3 Readout· SLE
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-09-19 · 1.5y away
SLE
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08052990 | NDA/BLA | SLE | Recruiting | 649 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 |